Psyence BioMed to Swap $5M Equity for 49.98% PsyLabs Stake
Psyence BioMed will acquire 2,900 PsyLabs shares valued at US$5.0 million via share-for-share exchange, issuing 1,146,159 new common shares based on a US$1,724 per-share valuation. Upon closing around February 25, PsyLabs will hold 49.98% of Psyence BioMed’s outstanding stock.
1. Transaction Details
Psyence BioMed will acquire 2,900 PsyLabs equity shares valued at US$5.0 million through a share-for-share exchange, issuing 1,146,159 new common shares based on a US$1,724 per-share valuation. The transaction is expected to close on or about February 25, 2026, subject to customary closing conditions.
2. Strategic Rationale
The equity swap strengthens the strategic alignment between Psyence BioMed and PsyLabs by securing long-term access to pharmaceutical-grade psychedelic compound manufacturing. The deal supports Psyence’s supply chain strategy as its clinical and commercialization programs for psilocybin and ibogaine therapies advance.
3. Governance and Approval
The Board of Psyence BioMed has approved the investment, and an independent Special Committee of disinterested directors reviewed and ratified the transaction based on its commercial rationale and a third-party valuation. Closing conditions include delivery of fair market value documentation by PsyLabs and confirmation of no material adverse events.